SEC Form 4 · accession 0001209191-16-142264
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Hirsch
Officer — Chief Financial Officer
Period of report
Sep 20, 2016
Accepted (ET)
Sep 21, 2016 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $49.83 | Sep 20, 2016 | A | 125,000 | A | — | Sep 19, 2026 | Common stock | 125,000 | 125,000 | D |
Explanation of responses
- F1This option was granted on September 20, 2016. The shares underlying this option vest as to 25% of the underlying shares on September 19, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.